

Ad-hoc-News

(Publication of insider information in accordance with Article 17 MAR)

Darwin AG acquires all shares in MEDICOPHARM AG

Munich, December 19, 2024

Darwin AG (ISIN DE000A3C35W0) has acquired all shares in MEDICOPHARM AG Arzneimittel und Medikal Produkte (hereinafter "Medicopharm"), based in Nußdorf am Inn, with a purchase agreement dated today. Medicopharm is active in the manufacture and distribution of pharmaceuticals and thus complements Darwin AG's existing portfolio in this sector.

According to the management board of Darwin AG, the acquisition will have a significant impact on the group's earnings situation. The parties have agreed not to disclose the economic details of the transaction.

Background

The "Darwin Group" (i.e. Darwin AG including its subsidiaries), headquartered in Munich (Germany), is a European biotechnology company, particularly in the field of human genetics. The genetic analysis carried out in our own laboratory are used in diagnostics, therapy and prevention of diseases as well as in the production of individually designed nutritional supplements and cosmetics. Darwin also acts as a partner for doctors, therapists, pharmacists, nutritionists or fitness trainers and, by analyzing the respective genetic predisposition of the patient or customer, helps to ensure the best possible treatment or care for their needs. Darwin also invests in innovative companies in the biotech, healthcare and life sciences sectors.

Contact:

Darwin AG

Brienner Str. 7

80333 München

Tel: +49 89 / 20 500 450

investor.relations@darwin-biotech.com